Dr. Lakshmi Rajdev
Claim this profileSiteman Cancer Center at Washington University
Studies Lymphoma
Studies Lung Cancer
2 reported clinical trials
4 drugs studied
Area of expertise
1Lymphoma
Stage IV
CD4+ cell count positive
CD4+ cell count negative
2Lung Cancer
Stage IV
CD4+ cell count positive
CD4+ cell count negative
Affiliated Hospitals
Clinical Trials Lakshmi Rajdev is currently running
Nivolumab + Ipilimumab
for Cancer
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory), or solid tumors that have spread from where it first started to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ipilimumab is an antibody that acts against a molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 controls a part of the immune system by shutting it down. Nivolumab is a type of antibody that is specific for human programmed cell death 1 (PD-1), a protein that is responsible for destruction of immune cells. Giving ipilimumab with nivolumab may work better in treating patients with HIV associated classical Hodgkin lymphoma or solid tumors compared to ipilimumab with nivolumab alone.
Recruiting1 award Phase 127 criteria
Atezolizumab + Chemotherapy
for Stomach and Esophageal Cancer
This phase II trial compares atezolizumab in combination with chemotherapy (docetaxel, oxaliplatin, leucovorin calcium, fluorouracil, capecitabine) to atezolizumab alone for controlling the growth and/or spreading of the disease in patients with gastric or gastroesophageal junction (JEG) cancer that has not spread from where it first started (local) or only has spread to nearby lymph nodes or tissue (locoregional) and has high microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR). The mismatch repair (MMR) system in the body corrects errors made during the copying of DNA and serves as a proofreading function. If this system isn't working correctly, mutations (changes) in DNA occur which can allow the cancer to grow or spread. This is called dMMR (deficient mismatch repair) . MSI-H describes cancer cells that have a high number of mutations within microsatellites. For example, microsatellite testing that shows mutations in 30% or more microsatellites is called microsatellite instability-high (MSI-H). Microsatellites are short, repeated sequences of DNA. There is evidence that MSI-H/ dMMR gastric or GEJ tumors respond well to immunotherapy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill tumor cells. Capecitabine is in a class of medications called antimetabolites. It is taken up by tumor cells and breaks down into fluorouracil, a substance that kills tumor cells. Chemotherapy drugs such as leucovorin calcium and fluorouracil work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Using atezolizumab as immunotherapy with and following chemotherapy versus atezolizumab alone prior to and after surgery may shrink or stabilize the tumor in patients with MSI-H/dMMR localized gastric or GEJ cancer and may increase the length of time after treatment that cancer does not come back or get worse.
Recruiting1 award Phase 2
More about Lakshmi Rajdev
Clinical Trial Related8 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Lakshmi Rajdev has experience with
- Ipilimumab
- Nivolumab
- Atezolizumab
- Oxaliplatin, Capecitabine, Docetaxel, Fluorouracil, Leucovorin Calcium
Breakdown of trials Lakshmi Rajdev has run
Lung Cancer
Kaposi Sarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lakshmi Rajdev specialize in?
Lakshmi Rajdev focuses on Lymphoma and Lung Cancer. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are CD4+ cell count positive.
Is Lakshmi Rajdev currently recruiting for clinical trials?
Yes, Lakshmi Rajdev is currently recruiting for 2 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Lakshmi Rajdev has studied deeply?
Yes, Lakshmi Rajdev has studied treatments such as Ipilimumab, Nivolumab, Atezolizumab.
What is the best way to schedule an appointment with Lakshmi Rajdev?
Apply for one of the trials that Lakshmi Rajdev is conducting.
What is the office address of Lakshmi Rajdev?
The office of Lakshmi Rajdev is located at: Siteman Cancer Center at Washington University, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Siteman Cancer Center at Washington University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.